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PODIUM SESSION I: HTA IN CANCER STUDIES AND METHODS
CN1
EFFICACY OF THE COMBINATION BEVACIZUMAB PLUS 
CHEMOTHERAPY (BEV-CT) COMPARED TO CT ALONE IN PREVIOUSLY 
UNTREATED LOCALLY ADVANCED OR METASTATIC NON-SMALL 
CELL LUNG CANCER (NSCLC): SYSTEMATIC REVIEW (SR) AND 
META-ANALYSIS (MA)
Botrel TEA, Clark O, Clark LGO, Paladini L, Faleiros E, Pegoretti B
MedInsight-Evidências, Campinas, Brazil
OBJECTIVES: To perform SR with MA of all randomized controlled trials (RCT) 
comparing the efﬁ cacy of BEV-CT versus CT alone in previously untreated locally 
advanced or metastatic NSCLC. METHODS: We searched MEDLINE, EMBASE, 
LILACS, and CENTRAL among others. Primary end points were overall survival (OS) 
and progression-free survival (PFS). Adverse events (AE) were analyzed. Extracted 
data were combined using hazard ratio (HR) or risk ratio (RR) with 95% conﬁ dence 
intervals (CI 95%). RESULTS: 544 references were identiﬁ ed and screened, three trials 
comprising 2020 patients were included. Overall response rate (RR = 0.53; CI 95% 
= 0.44 to 0.64; P < 0.00001) and PFS were higher in BEV-CT (HR = 0.71, CI 95% 
= 0.63 to 0.80; P < 0.00001), however with signiﬁ cant heterogeneity (χ2 = 4.9, df = 
2 [P = 0.09]; I2 = 59%) and (χ2 = 4.33, df = 2 [P = 0.11]; I2 = 54%), respectively. 
Random-efffects model analysis favored BEV-CT. OS was higher in BEV-CT but with 
signiﬁ cant heterogeneity (χ2 = 5.92, df = 3 [P = 0.12]; I2 = 49%) and random-effects 
model analysis was not statistically signiﬁ cant (HR = 0.86, CI 95% = 0.71 to 1.05; P 
= 0.15). Neutropenia (RR = 0.77; CI 95% = 0.65 to 0.91; P = 0.002) and febrile 
neutropenia (RR = 0.42; CI 95% = 0.22 to 0.81; P = 0.009) were higher on BEV-CT. 
Rates of anemia (RR = 1.41; CI 95% = 0.93 to 2.13; P = 0.1) and thrombocytopenia 
(RR = 0.91; CI 95% = 0.69 to 1.20; P = 0.50) were similar. Non-hematologic toxicities 
were higher on BEV-CT: hemoptysis (RR = 0.28; CI 95% = 0.09 to 0.90; P = 0.03), 
hypertension (RR = 0.15; CI 95% = 0.07 to 0.30; P < 0.00001), proteinuria (RR = 
0.05; CI 95% = 0.01 to 0.41; P = 0.005), venous thromboembolic events (RR = 0.87; 
CI 95% = 0.51 to 1.47; P = 0.6), vomiting (RR = 0.41; CI 95% = 0.22 to 0.77; P = 
0.005), rash (RR = 0.19; CI 95% = 0.04 to 0.88; P = 0.03), epistaxis (RR = 0.32; CI 
95% = 0.03 to 3.10; P = 0.33) and bleeding events (RR = 0.27; CI 95% = 0.13 to 
0.56; P = 0.0004). CONCLUSIONS: The combination BEV-CT increased the response 
rate and PFS in patients with NSCLC. Beneﬁ ts in overall survival remain uncertain, 
and toxicity rates were higher in the combination group.
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REAL-WORLD COST-EFFECTIVENESS OF OXALIPLATIN IN STAGE III 
COLON CANCER: A SYNTHESIS OF TRIAL DATA WITH DATA FROM 
DAILY CLINICAL PRACTICE
van Gils C, de Groot S, Redekop W, Uyl-de Groot C
Erasmus University, Rotterdam, The Netherlands
OBJECTIVES: Previous cost-effectiveness analyses of oxaliplatin have been based on 
randomized trial settings which may not reﬂ ect actual daily practice. The objective of 
this study was to examine the real-world cost-effectiveness of oxaliplatin plus ﬂ uoro-
pyrimidines versus ﬂ uoropyrimidines only, as adjuvant treatment of colon cancer. 
METHODS: A Markov model was developed to estimate lifetime costs and quality-
adjusted life-years (QALYs) from a hospital perspective. Dutch real-world (RW) 
population-based data on use, costs, and disease-free survival after oxaliplatin use 
were combined with published efﬁ cacy data from the pivotal clinical registration trial 
(MOSAIC trial). Eighty-two percent of the patients in the RW study fulﬁ lled the 
MOSAIC trial eligibility criteria (“eligibles”); the other 18% (“ineligibles”) had a 
poorer prognosis. The efﬁ cacy of the comparator was modelled using MOSAIC trial 
results. Cost-effectiveness analyses (CEAs) were performed for four different scenarios: 
1) CEA based on MOSAIC trial patients; 2) CEA using eligible RW patients; 3) CEA 
using both eligibles and ineligibles, assuming that oxaliplatin had an equal effect in 
both groups; and 4) CEA using eligibles and ineligibles, assuming oxaliplatin had no 
effect among ineligibles. RESULTS: MOSAIC and eligible RW patients had similar 
2-year disease-free survivals (79% vs. 78%). Oxaliplatin showed an incremental 
QALY gain of 0.86, 0.73, 0.81, and 0.60, and incremental costs of c13,105, c13,278, 
c13,225, and c13,456 in scenarios 1 to 4, respectively. The corresponding incremental 
cost-effectiveness ratios (ICERs) were c15,185, c18,115, c16,254, and c22,387 in 
scenarios 1 to 4, respectively. Sensitivity analyses of input parameters and model 
assumptions produced only minimal differences in the estimated ICERs showing the 
robustness of the model results. CONCLUSIONS: The real-world cost-effectiveness 
of oxaliplatin plus ﬂ uoropyrimidine versus ﬂ uoropyrimidine for the treatment of colon 
cancer can be estimated using different scenarios. We found that the various estimates 
were very similar, and all suggest that oxaliplatin is cost-effective.
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1Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland; 
2HealthQuest sp.z o.o., Warsaw, Poland
OBJECTIVES: Cancer is a leading cause of death worldwide and major health 
problem. It’s also a huge problem to worldwide economy due to high both direct and 
indirect costs. The aim of this study was to evaluate absenteeism costs of cancer in 
Poland in 2007. METHODS: Sickness absence data and data on disability were 
derived by ZUS (Social Insurance Institution). Costs of lost productivity due to pre-
mature death were estimated based on regional register data on cancer mortality 
(KRN—National Cancer Registry). Absenteeism costs were estimated based on gross 
value added per employee derived by Central Statistical Ofﬁ ce (GUS). The analyses 
of indirect costs due to sickness absence were based on an assumption that number 
of missed days includes only working days (226 days per year). Human capital 
approach was used to estimate the absenteeism costs. Values are presented in Euro 
(exchange rate: 1 EUR = 4.10 PLN). RESULTS: Costs of lost productivity due to 
illness and disability were estimated to amount of c1081 million (c451 and c630 
million, respectively). Costs of lost productivity due to premature death were estimated 
to amount of c4692 million and were twice as high in male population compare to 
female population (c3200 and c1492 million, respectively). The highest costs of lost 
productivity due to premature death were related to lung cancer (c1331 million) fol-
lowed by brain (c356 million), stomach (c314 million), and breast cancer (c259 
million). Lung cancer was the leading cost of lost productivity due to premature death 
in male population (c917 million), while breast cancer dominated in female population 
(c255 million). CONCLUSIONS: Indirect costs of lost productivity due to cancer-
related illness, disability, and premature death are substantial to polish economy and 
may account for near 0.6% of PKB loss in 2007 year.
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HPV-BASED PRIMARY CERVICAL CANCER SCREENING IN GERMANY. 
COST-EFFECTIVENESS RESULTS FROM A DECISION-ANALYTIC 
MODELING STUDY
Sroczynski G1, Schnell-Inderst P1, Muehlberger N1, Lang K2, Aidelsburger P2, Wasem J3, 
Mittendorf T4, Engel J5, Hillemanns P6, Petry K-U6, Kraemer A7, Siebert U1
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Sciences, Medical Informatics and Technology, Hall i.T., Austria; 2CAREM GmbH, Sauerlach, 
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Germany; 4Institute for Health Economics, University of Hanover, Hanover, Germany; 
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OBJECTIVES: The objective of this HTA commissioned by the German Agency for 
Health Technology Assessment (DAHTA@DIMDI) and the Federal Ministry of Health 
was to systematically evaluate the long-term effectiveness and cost-effectiveness of 
HPV-based primary cervical cancer screening for the German health care context using 
a decision analytic approach. METHODS: A Markov model simulating the natural 
history of cervical cancer was developed and validated for the German health care 
context. Different screening strategies were evaluated, including cytology alone, HPV 
testing alone or combined with cytology or with cytological triage for HPV-positive 
women, and different screening intervals. German clinical, epidemiological and eco-
nomic data were used. Test accuracy data were retrieved from international meta-
analyses. Predicted outcomes were reduction in cervical cancer cases and deaths, life 
expectancy, and discounted incremental cost-effectiveness ratios (ICER). a perspective 
of the health care system and 3% annual discount rate were adopted. Extensive 
sensitivity analyses were performed to evaluate robustness of results. RESULTS: HPV-
based screening was more effective than cytology alone, with 71%–97% (depending 
on screening intervals) relative reduction in cervical cancer compared to 53%–80% 
for cytology. The ICER ranged between c2,600/LYG (cytology, 5-yr-interval) and 
c155,500/LYG (annual HPV-testing age 30 yrs, cytology 20–29 yrs). Annual cytol-
ogy, the current recommended screening strategy in Germany, was dominated by other 
strategies. Increasing screening start-age to 25 yrs had no relevant loss in effectiveness 
but resulted in lower costs. CONCLUSIONS: Based on our analyses, HPV-based cervi-
cal cancer screening is more effective than cytology and could be cost-effective, when 
performed at intervals of 2 years or longer. For the German screening context, an 
optimal screening strategy could be biennial HPV testing starting at age 30 yrs and 
biennial cytology at the age 25–29 yrs. An extension to a 3-yearly screening interval 
may be considered for low-risk women with good screening adherence or in popula-
tions with low HPV incidence. 
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